Related Experiment Video
Updated: Feb 14, 2026
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against
Nicole LoGiudice1, Linh Le2, Irene Abuan3
1Pacific University School of Pharmacy, Hillsboro, OR 97123, USA. logi8930@pacificu.edu.
Abstract:
The fluorinated ornithine analog α-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis. The ubiquitous and essential polyamines have many functions, but are primarily important for rapidly proliferating cells. Thus, ODC is potentially a drug target for any disease state where rapid growth is a key process leading to pathology. The compound was originally discovered as an anticancer drug, but its effectiveness was disappointing. However, DFMO was successfully developed to treat African sleeping sickness and is currently one of few clinically used drugs to combat this neglected tropical disease. The other Food and Drug Administration (FDA) approved application for DFMO is as an active ingredient in the hair removal cream Vaniqa. In recent years, renewed interest in DFMO for hyperproliferative diseases has led to increased research and promising preclinical and clinical trials. This review explores the use of DFMO for the treatment of African sleeping sickness and hirsutism, as well as its potential as a chemopreventive and chemotherapeutic agent against colorectal cancer and neuroblastoma.
Insights
α-difluoromethylornithine (DFMO) inhibits ornithine decarboxylase, crucial for rapidly growing cells. Originally for cancer, DFMO now treats sleeping sickness and hirsutism, with renewed potential in cancer chemoprevention and therapy.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Polyamines are essential for rapidly proliferating cells.
- Ornithine decarboxylase (ODC) is the rate-limiting enzyme in polyamine biosynthesis.
- ODC is a potential drug target for diseases characterized by rapid cell growth.
Purpose of the Study:
- To review the therapeutic applications of DFMO.
- To explore DFMO's potential in treating African sleeping sickness, hirsutism, colorectal cancer, and neuroblastoma.
- To highlight DFMO's role in chemoprevention and chemotherapy.
Main Methods:
- Literature review of DFMO's mechanism of action and clinical applications.
- Analysis of preclinical and clinical trial data for DFMO in various diseases.
- Exploration of DFMO's efficacy as an irreversible suicide inhibitor of ODC.
Main Results:
- DFMO is an effective treatment for African sleeping sickness and hirsutism.
- Initial anticancer applications of DFMO were disappointing.
- Renewed research shows promising preclinical and clinical results for DFMO in hyperproliferative diseases.
Conclusions:
- DFMO is a clinically approved drug with established uses in neglected tropical diseases and cosmetic applications.
- DFMO demonstrates significant potential as a chemopreventive and chemotherapeutic agent against cancers like colorectal cancer and neuroblastoma.
- Further research and clinical trials are warranted to fully realize DFMO's therapeutic potential in oncology.
Related Concept Videos
01:14Reversible and Irreversible Processes
01:24Biosynthesis in Bacteria
01:26Biosynthesis of Polysaccharides
01:29Biosynthesis of Lipids
01:28Biosynthesis of Nucleic Acids
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...